CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Clinical trials for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) explained in plain language.
Never miss a new study
Get alerted when new CLEAR CELL RENAL CELL CARCINOMA (CCRCC) trials appear
Sign up with your email to follow new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug combo may help save kidneys in High-Risk cancer patients
Disease control Recruiting nowThis study tests whether giving two drugs (pucotenlimab and vorolanib) before surgery can shrink kidney tumors enough to allow partial kidney removal instead of full removal. About 21 adults with high-risk clear cell renal cell carcinoma will receive the drug combination for seve…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 17, 2026 03:17 UTC
-
New drug combo hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs shrink tumors. About 240 parti…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:15 UTC
-
New hope for advanced cancers? XL092 combo enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 17, 2026 03:14 UTC
-
New hope for kidney cancer: Triple-Drug combo trial launches
Disease control Recruiting nowThis study tests three different drug combinations in 120 people with advanced kidney cancer that has spread. The goal is to see which combination works best at shrinking tumors. Participants will receive either a new two-drug or three-drug combo, or the current standard treatmen…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE2 • Sponsor: Brian Rini • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-stage study tests a new drug called KO-2806 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors, either alone or combined with other therapies. About 300 adults wi…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called REGN5678, alone or with another drug (cemiplimab), in people with advanced prostate or kidney cancer that has spread. The goal is to find safe doses and see if the drugs can shrink tumors by helping the immune system attack cancer cells. About 3…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC